Prostate-Specific Antigen Levels Among Diabetic Men: Exploring Patients Attending Outpatient Clinic in Yemen
Men's Health Journal,
Vol. 4 No. 1 (2020),
19 April 2020
Introduction: It has been reported that patients with diabetes have a decreased risk for developing prostate cancer. The study aimed to measure Prostate-specific antigen (PSA) levels among diabetic men who had not previously been diagnosed with prostate cancer. Materials and Methods: A cross-sectional study was carried out in public hospitals among diabetic men in Aden, Yemen. A predesigned structured questionnaire, including the personal data as well as physical and clinical characteristics of the study population, such as height, weight, smoking status, the duration of diabetes, and the type of treatment, was included. Blood samples were collected from the respondents, and the levels of fasting blood glucose (FBG) and PSA were measured. The data were analyzed using descriptive and inferential statistics. Results: A total of 145 diabetic male patients were included in this study. The mean PSA level of the respondents was 2.56 ng/ml. There were significant differences in PSA levels according to patient age (p=0.000). The elderly patients exhibited significantly higher PSA levels than the younger groups. The PSA levels of smokers (2.60±0.48 ng/ml) were significantly higher (p=0.035) than those of nonsmokers (2.45±0.65 ng/ml). However, no significant difference was found in PSA levels according to body mass index (BMI) category, the type of treatment, or the duration of diabetes. Additionally, our results showed that PSA levels were not significantly correlated with FBG levels. Conclusion: PSA levels were associated with age and smoking status, but not with BMI, the type of diabetic treatment, the duration of diabetes, or with FBG levels.
How to Cite
Diamandis EP. Prostate-specific antigen: its usefulness in clinical medicine. Trends in Endocrinology & Metabolism. 1998;9(8):310-6.
Thompson I, Carroll P, Coley C, Sweat G, McLeod D, Schellhammer P, et al. Prostate-specific antigen (PSA) best practice policy. Oncology. 2000;14(2):267-86.
Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. The Journal of clinical investigation. 1985;76(5):1899-903.
Seikkula H, Syvänen KT, Kurki S, Mirtti T, Taimen P, Laato M, et al., editors. Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations; 2015: Elsevier.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate international. 2015;3(4):135-40.
Organization WH. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health Organization; 1999.
Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071-8.
Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology and Prevention Biomarkers. 2006;15(11):2056-62.
Control CfD, Prevention, Health UDo, Services H. National diabetes fact sheet: General information and national estimates on diabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. 2005.
Di Sebastiano K. Glucose Metabolism in High-Risk Prostate Cancer Patients throughout the Acute Disease Trajectory. 2016.
Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71(5):787-91.
Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, et al. Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiology and Prevention Biomarkers. 2007;16(1):70-6.
Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, et al. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. European Journal of Cancer. 2007;43(7):1180-7.
Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006;106(2):320-8.
Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. American journal of epidemiology. 2005;161(2):147-52.
Tavani A, Gallus S, Bosetti C, Tzonou A, Lagiou P, Negri E, et al. Diabetes and the risk of prostate cancer. European journal of cancer prevention. 2002;11(2):125-8.
Elabbady A, Hashad MM, Kotb AF, Ghanem AE. Studying the effect of type 2 diabetes mellitus on prostate-related parameters: A prospective single institutional study. Prostate international. 2016;4(4):156-9.
Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. American journal of epidemiology. 2009;169(8):937-45.
Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate cancer and prostatic diseases. 2013;16(2):151-8.
Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, et al. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes care. 2008;31(5):930-1.
Müller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiology and Prevention Biomarkers. 2009;18(5):1350-6.
Naito M, Asai Y, Mori A, Fukada Y, Kuwabara M, Katase S, et al. Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya journal of medical science. 2012;74(3-4):285.
Tseng C-H. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care. 2011;34(3):616-21.
Gunaid A, Assabri A. Prevalence of type 2 diabetes and other cardiovascular risk factors in a semirural area in Yemen. EMHJ-Eastern Mediterranean Health Journal, 14 (1), 42-56, 2008. 2008.
Organization WH. Physical status: The use of and interpretation of anthropometry, Report of a WHO Expert Committee: World Health Organization; 1995.
Bakir MA, Abo-Daher D. Age-specific reference ranges for prostate-specific antigen among healthy Syrian men. The International Journal of Biological Markers. 2012;27(2):152-9.
Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, et al. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Canadian Urological Association Journal. 2011;5(6):416.
Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomarkers in medicine. 2011;5(4):515-26.
DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, et al. Age-and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996;48(2):234-9.
Malati T, Kumari GR. Racial and ethnic variation of PSA in global population: age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian Journal of Clinical Biochemistry. 2004;19(1):132.
Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian journal of urology. 2017;4(2):86-95.
Rabah DM, Farhat KH, Al-Atawi MA, Arafa MA. Age-specific reference ranges of prostate-specific antigen among Saudi men as a representation of the Arab population. Medical Principles and Practice. 2019;28(3):242-6.
Arab D, Zadeh AA, Mirmohammadkhani M, Beiglarzadeh A. Prostate-specific antigen rising in Iranian men in correlation with body mass index, fasting blood sugar and blood lipid profile. Journal of Nephropathology. 2016;5(4):134.
Lee SE, Kwak C, Park MS, Lee CH, Kang W, Oh S-J. Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population. Urology. 2000;56(6):1007-10.
Ikuerowo SO, Ajala MO, Abolarinwa AA, Omisanjo OA. Age-specific serum prostate specific antigen ranges among apparently healthy Nigerian men without clinical evidence of prostate cancer. Nigerian Journal of Surgery. 2016;22(1):5-8.
Müezzinoğlu T, Lekili M, Eser E, Uyanık BS, Büyüksu C. Population standards of prostate specific antigen values in men over 40: community based study in Turkey. International urology and nephrology. 2005;37(2):299-304.
Abdalla I, Ray P, Ray V, Vaida F, Vijayakumar S. Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology. 1998;51(2):300-5.
Al-Asadi JN, Al-Naama LM, Abdul-Kareem MM, Mashkoor FC. Serum level of prostate-specific antigen in diabetic patients in Basrah, Iraq. Nigerian Postgraduate Medical Journal. 2017;24(4):240.
Ainahi A, Brakat A, Wakrim L, Mohammadi H, ElMdaghri N, Ezzikouri S. Prostate-specific Antigen Levels in Moroccan Diabetic Males: A Cross-sectional Study. Current diabetes reviews. 2018;14(3):286-90.
Rastmanesh R, Hejazi J, Marotta F, Hara N. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clinical genitourinary cancer. 2014;12(3):143-8.
Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, Sauver JLS, Jacobsen SJ, et al. The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology. 2011;77(1):137-41.
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. Jama. 1993;270(7):860-4.
Cvitkovic L, Pavlic-Renar I, Rocic B. prostate specific antigen and type 2 diabetes: a preliminary report. Diabetol Croat. 2001;30(4):121-24.
Sawyer R, Berman JJ, Borkowski A, Moore GW. Elevated prostate-specific antigen levels in black men and white men. Modern Pathology: an Official Journal of the United States and Canadian Academy of Pathology, Inc. 1996;9(11):1029-32.
Barry MJ. Prostate-specific–antigen testing for early diagnosis of prostate cancer. New England Journal of Medicine. 2001;344(18):1373-7.
Thompson IM, Leach R, Troyer D, Pollock B, Naylor S, Higgins B, editors. Relationship of body mass index and prostate specific antigen in a population-based study☆. Urologic Oncology: Seminars and Original Investigations; 2004: Elsevier.
Chia SE, Lau WK, Chin CM, Tan J, Ho SH, Lee J, et al. Effect of ageing and body mass index on prostate‐specific antigen levels among Chinese men in Singapore from a community‐based study. BJU international. 2009;103(11):1487-91.
Ando R, Nagaya T, Hashimoto Y, Suzuki S, Itoh Y, Umemoto Y, et al. Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004-2006. Urology. 2008;72(3):561-5.
Chang IH, Ahn SH, Han JH, Kim T-H, Kim YS, Myung SC. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration. The Journal of urology. 2009;181(2):567-73.
Kubota Y, Seike K, Maeda S, Shinohara Y, Iwata M, Sugimoto N. Relationship between prostate‐specific antigen and obesity in prostate cancer screening: Analysis of a large cohort in Japan. International Journal of Urology. 2011;18(1):72-5.
MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer causes & control. 2006;17(8):989-1003.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet. 2008;371(9612):569-78.
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiology and Prevention Biomarkers. 2006;15(10):1977-83.
Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiologic reviews. 2007;29(1):88-97.
Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;109(4):675-84.
Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology and Prevention Biomarkers. 2007;16(1):63-9.
Choi JB, Moon HW, Park YH, Bae WJ, Cho HJ, Hong S-H, et al. The impact of diabetes on the risk of prostate cancer development according to body mass index: a 10-year nationwide cohort study. Journal of Cancer. 2016;7(14):2061.
Beckmann K, Crawley D, Nordström T, Aly M, Olsson H, Lantz A, et al. Association between antidiabetic medications and prostate-specific antigen levels and biopsy results. JAMA network open. 2019;2(11):e1914689-e.
Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, et al. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World journal of urology. 2015;33(8):1189-96.
Park JS, Lee KS, Ham WS, Chung BH, Koo KC. Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008. Medicine. 2017;96(51).
Koc G, Akgul K, Yilmaz Y, Dirik A, Un S. The effects of cigarette smoking on prostate-specific antigen in two different age groups. Canadian Urological Association Journal. 2013;7(11-12):E704.
Gray MA, Delahunt B, Fowles JR, Weinstein P, Cooke RR, Nacey JN. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer research. 2004;24(3B):2069-72.
Gelmann EP, Chia D, Pinsky PF, Andriole GL, Crawford ED, Reding D, et al. Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology. 2001;58(4):561-6.
Li J, Thompson T, Joseph DA, Master VA. Association between smoking status, and free, total and percent free prostate specific antigen. The Journal of urology. 2012;187(4):1228-33.
Mohammed MM, Abdulridha MK, Al–MullaHummadi YMK. Body Mass Index (BMI), lipid profile, leptin level and their correlation with Prostate Specific Antigen (PSA) in Iraqi patients with Benign Prostatic Hyperplasia (BPH). karbala journal of pharmaceutical sciences. 2013(4):18-31.
Han JH, Chang IH, Ahn SH, Kwon OJ, Bang SH, Choi NY, et al. Association between serum prostate‐specific antigen level, liver function tests and lipid profile in healthy men. BJU international. 2008;102(9):1097-101.
- Abstract Viewed: 0 times
- pdf Downloaded: 0 times